| Literature DB >> 21718478 |
Mia Johansson1, Anna Rydén, Caterina Finizia.
Abstract
BACKGROUND: Using a longitudinal design, aim of this study was to investigate the relation between mental adjustment to cancer and anxiety, depression, health-related quality of life (HRQL) and survival in patients treated for laryngeal cancer.Entities:
Mesh:
Year: 2011 PMID: 21718478 PMCID: PMC3136424 DOI: 10.1186/1471-2407-11-283
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Sociodemographic and clinical characteristics of participants and non-participants
| Participants (n = 100) | Non-participants (n = 110) | ||
|---|---|---|---|
| Age, mean years (SD) | 67 (11.4) | 69 (10.11) | ns |
| Sex | ns | ||
| Female | 17 (17%) | 22 (20%) | |
| Male | 83 (83%) | 88 (80%) | |
| Tumour site | |||
| Glottic | 72 (72%) | 61 (55%) | 0.0188 |
| Supraglottic | 20 (20%) | 37 (34%) | 0.0382 |
| Subglottic | 4 (4%) | 3 (3%) | ns |
| Transglottic | 4 (4%) | 9 (8%) | ns |
| Stage | |||
| 0 | 3 (3%) | 2 (2%) | |
| I | 57 (57%) | 43 (39%) | |
| II | 22 (22%) | 24 (22%) | |
| III | 9 (9%) | 17 (15%) | |
| IV | 9 (9%) | 24 (22%) | 0.001 |
| Karnofsky performance scale | |||
| 100 | 60 (63%) | 34 (33%) | |
| 90 | 23 (24%) | 33 (31%) | |
| 80 | 8 (8%) | 20 (19%) | |
| 70 | 3 (3%) | 12 (11%) | |
| 60 | 0 (0%) | 1 (1%) | |
| 50 | 1 (1%) | 1 (1%) | |
| 40 | 0 (0%) | 4 (4%) | >0.001 |
| Married/Cohabitant | 70 (70%) | 62 (56%) | ns |
| Smokers | 50 (50%) | 70 (64%) | ns |
| Loss of weight | 21 (21%) | 35 (32%) | ns |
| Residual disease | 2 (2%) | 2 (2%) | ns |
| Cardiovascular disease | 45 (45%) | 38 (35%) | ns |
| Other malignancy | 8 (8%) | 11 (10%) | ns |
p-value significant at ≤0.05, ns = not significant.
Participants were classified as N0M0, except one patient classified as N2M0 and two classified as N2M1. Among non-participants 10 patients were classified as N1M0, six as N2M0, one as N3M0 and one patient as N2M1.
Mean values, SD and range of scores for Mini-MAC domains one month and 12 months after start of treatment
| Baseline | Follow-up | Change | Baseline | |||
|---|---|---|---|---|---|---|
| Mean (SD) | Range | Mean (SD) | Range | Cronbach's alpha | ||
| 14.15 (5.09) | 8-29 | 12.28 (4.07) | 8-26 | 0.01 | 0.85 | |
| 1.77 (0.64) | 1-3.63 | 1.54 (0.51) | 1-3.25 | |||
| 10.52 (3.34) | 4-16 | 10.94 (3.07) | 4-16 | ns | 0.74 | |
| 2.63 (0.84) | 1-4 | 2.74 (0.77) | 1-4 | |||
| 13.53 (2.99) | 5-20 | 12.87 (3.09) | 7-20 | 0.01 | 0.61 | |
| 2.71 (0.60) | 1-4 | 2.57 (0.62) | 1.4-4 | |||
| 12.15 (2.58) | 4-16 | 11.76 (2.57) | 7-16 | ns | 0.50 | |
| 3.04 (0.64) | 1-4 | 2.94 (0.64) | 1.75-4 | |||
| 9.97 (3.19) | 8-28 | 9.76 (3.56) | 8-5 | ns | 0.81 | |
| 1.25 (0.40) | 1-3.5 | 1.22 (0.44) | 1-3.13 | |||
AP = Anxious Preoccupation, CA = Cognitive Avoidance, FA = Fatalism, FS = Fighting Spirit, HH = Helpless-Hopeless
*Min-Max scores of AP 8-32; CA 4-16; FA 5-20; FS 4-16;HH 8-32
**Min-Max 1-4 (mean computed by dividing total sum with number of items)
† p-value significant at ≤0.05
ns = not significant, Wilcoxon's signed rank test
Number of false significances is calculated to 0.16.
Mini-MAC correlations with HADS, EORTC QLQ-C30, EORTC QLQ-H&N35 and age, one month and 12 months after start of treatment
| Anxious Preoccupation | Cognitive Avoidance | Fatalism | Fighting Spirit | Helpless-Hopeless | |
|---|---|---|---|---|---|
| 1 month | 0.66 (<0.0001) | -0.11 | -0.12 | -0.17 | 0.50 (<0.0001) |
| 12 months | 0.59 (<0.0001) | -0.16 | -0.11 | -0.36 (0.002) | 0.58 (<0.0001) |
| 1 month | 0.56 (<0.0001) | -0.32 | -0.09 | -0.14 | 0.52 (<0.0001) |
| 12 months | 0.58 (<0.0001) | -0.14 | -0.06 | -0.20 | 0.62 (<0.0001) |
| 1 month | -0.63 (<0.0001) | 0.02 | 0.02 | 0.11 | -0.46 (<0.0001) |
| 12 months | -0.52 (<0.0001) | 0.10 | 0.14 | 0.31 (0.008) | -0.49 (<0.0001) |
| 1 month | -0.39 (<0.0001) | 0.01 | 0.13 | 0.13 | -0.34 (0.0007) |
| 12 months | -0.45 (<0.0001) | 0.06 | 0.16 | 0.35 (0.003) | -0.30 (0.01) |
| 1 month | -0.36 (0.0003) | 0.09 | 0.02 | -0.03 | -0.34 (0.0007) |
| 12 months | -0.44 (0.0001) | 0.17 | 0.18 | -0.08 | -0.33 (0.004) |
| 1 month | -0.39 (<0.0001) | -0.035 | -0.03 | -0.03 | -0.30 (0.003) |
| 12 months | -0.56 (<0.0001) | -0.12 | 0.15 | -0.37 (0.002) | -0.53 (<0.0001) |
| 1 month | 0.41 (<0.0001) | -0.06 | 0.13 | 0.08 | 0.36 (0.0004) |
| 12 months | 0.28 (0.018) | -0.15 | -0.03 | -0.15 | 0.24 (0.039) |
Spearman correlation coefficients (significant p-value).
Number of false significances is calculated to 2.
Univariate survival analysis
| Variable | Hazard Ratio (95% CI) | Cox |
|---|---|---|
| 1.049 (1.013-1.086) | 0.007 | |
| cis+I+II | 2.082 (1.008-4.301) | 0.048 |
| married/cohabitant | 0.501 (0.262-0.957) | 0.036 |
| Glottic | 0.315 (0.166-0.597) | <0.001 |
| 0.949 (0.921-0.977) | 0.001 | |
| 2.727 (1.060-7.013) | 0.037 | |
| 1.168 (1.067-1.279) | 0.001 |
Number of false significances is calculated to 0.
Multivariate survival analysis
| Variable | Hazard Ratio (95% CI) |
|---|---|
| 1.065 (1.02-1.11) | |
| cis+I+II | 1.149 (0.44-3.00) |
| glottic | 0.315 (0.13-0.74) |
| 1.234 (1.12-1.36) |